The biochemistry is real and the safety record is good, but the syllogism in the marketing has a hole in the middle: raising a biomarker is not the same as changing the thing the biomarker is a marker of. Every human NMN trial to date is small, short, and measures surrogate endpoints. Two 2024 meta-analyses found no significant effect on glucose control or lipids, and a 2025 meta-analysis concluded the evidence does not support NMN for preserving muscle in older adults.
Nicotinamide mononucleotide (NMN) is a naturally occurring nucleotide and a direct biosynthetic precursor of nicotinamide adenine dinucleotide (NAD+), a coenzyme essential for cellular energy metabolism, DNA repair, and the activity of sirtuin and PARP enzymes. NAD+ levels decline with age across many tissues, a process attributed in part to increased NAD+ consumption by the NADase CD38, and this decline has been linked to metabolic and age-related dysfunction. Oral NMN is sold as a dietary supplement intended to replenish NAD+ ('NAD+ boosting'), and it is one of several vitamin B3-related NAD+ precursors alongside nicotinamide riboside and nicotinamide-plus-ribose blends, which human trials also show can raise NAD+. Human trials consistently show that supplemental NMN raises circulating NAD+ and NAD+ metabolite levels.
Claims below are supported by the primary sources linked under each line — the same sources we cite on the product page.
Each line pairs a claim that circulates in marketing and forums with the trial result that contradicts or narrows it.
Quotations are verbatim from the cited paper. Negative and inconclusive trials are listed alongside the positive ones because that is the whole point of this page.
“Together, our findings suggest that an exaggeration of the benefits of NMN supplementation may exist in the field.”
“Current evidence does not support NMN and NR supplementation for preserving muscle mass and function in adults with mean age of over 60 years.”
“In older male patients with diabetes and impaired physical performance, NMN supplementation for 24 weeks was safe, but did not improve grip strength and walking speed.”
“Insulin-stimulated glucose disposal, assessed by using the hyperinsulinemic-euglycemic clamp, and skeletal muscle insulin signaling [phosphorylation of protein kinase AKT and mechanistic target of rapamycin (mTOR)] increased after NMN supplementation but did not change after placebo treatment.”
“Compared with the placebo, NMN supplementation was associated with a statistically significant but modest reduction in resting DBP (WMD, -2.15 mmHg; 95% CI: -3.68 to -0.61). In contrast, the reduction in resting SBP was not statistically significant.”
In randomized controlled trials, NMN reliably increases blood NAD+ levels and has generally been well tolerated at oral doses up to roughly 900-1250 mg/day, with some trials reporting modest improvements in skeletal-muscle insulin sensitivity, walking speed, aerobic capacity, sleep quality, and diastolic blood pressure. However, the human evidence is mixed and often preliminary: several meta-analyses found no significant benefit for glucose control, blood lipids, or muscle mass and strength, and multiple individual trials were null, prompting reviewers to caution that the benefits of NMN may be exaggerated relative to the striking results seen in mice. Trials so far are small (typically 25-80 participants), short (6-12 weeks), and measure surrogate endpoints, with no lifespan or disease-prevention outcomes; formulation-specific claims also outrun the data — no published human trial has tested liposomal NMN, so enhanced-absorption claims remain unverified. Larger, longer, higher-quality trials are still needed to establish whether NAD+ repletion produces clinically meaningful anti-aging effects in people. This evidence describes the NMN compound and NAD+ biology in general, not this specific commercial product, which has not itself been tested in the cited studies.
A grade that cannot be falsified is a marketing claim. These are the specific results that would move this one up.
NMN is cheap, well tolerated at studied doses, and does the one thing it says on the tin — it raises NAD+. If that is what you are buying, buy the plain, standardized, third-party-tested version at the studied dose and skip the liposomal premium, because nothing in the human record supports paying for it. If your actual goal is muscle, strength or metabolic health, the evidence points somewhere else entirely.
Other graded listings for the same compound: Nutricost NMN Capsules 500mg ($19.95) · NOVOS Boost NMN ($44.00) · NMN Complex 1000 mg (Micro Ingredients) ($34.95) · Purovitalis Liposomal β-NMN ($47.99) · DaVinci Labs NAD+ ACTIVATE ($27.12)
Graded Strong evidence for muscle and exercise performance — the best-supported ingestible in this catalogue, and roughly the goal most people buy NMN for.
What consistent randomized trials actually support, and what they do not.
Graded Strong. If a 2 mmHg diastolic change is the reason you are interested, measure the number rather than assume it.
If you are buying anyway: dose, purity, third-party testing and what to ignore on the label.
NMN molecule page · NAD+ pathway · NAD+ levels and aging · NMN vs NR: what the human trials show · Double Wood NMN: the evidence · Pathway universe · The graded supplement guide
Sibling pages in this record: Resveratrol · Vitamin D · Omega-3 fish oil · Blue-light filtering glasses
Yes. This is the part that is not in dispute: randomized, placebo-controlled trials show blood NAD+ and its metabolites rise reliably on oral NMN, in a dose-dependent way. The dispute is entirely about whether that rise produces a health outcome you would notice.
Trials have been reassuring at the doses studied. A dedicated safety study found 1,250 mg once daily safe and well tolerated for up to four weeks in healthy adults, and no dose-limiting toxicities were reported in a 2026 phase 1/2 clinical trial. Long-term safety beyond a few months has not been established, because trials that long have not been run.
There is no published human trial of a liposomal NMN product, so there is nothing to base that decision on except the label. The liposomal delivery research exists in cells and animals. We list liposomal NMN because people look for it, and we say this on the product page too.
Because Moderate is not zero. NMN raises NAD+, safety looks good, and a handful of trials show modest functional gains in specific populations. What we will not do is describe that as anti-aging, and this page is the version of the story we would want a family member to read before spending money.